OmniSeq News

OmniSeq Names Dr. Shengle Zhang as New Lab Director

FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...

Schoenborn named CEO at OmniSeq

June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.

People in the News

June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.

Margot Schoenborn becomes CEO of fast-growing OmniSeq

Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

Follow Us on Twitter

Thank you to the many OmniSeq partners and followers who have been a part of our community! We appreciate your support and are looking forward to continuing the conversation around cancer diagnostics now that OmniSeq is part of Labcorp. Join us here: http://spr.ly/60113sQzZ

OmniSeq® is now part of Labcorp. Be sure to follow Labcorp to stay up-to-date on the latest #oncology updates. We look forward to providing timely and relevant information about how we are driving precision cancer care forward: https://bit.ly/3BdrZUu

This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Load More...